Rezolute stock crashes after sole pipeline candidate fails Phase III
Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215), ersodetug, …
Post
-
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, …
-
AI takes charge of data, but challenges linger
For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been …
-
FDA grants clearance to Prilenia and Ferrer’s Phase III ALS therapy trial
The US Food and Drug Administration (FDA) has granted clearance to Prilenia Therapeutics and Ferrer to commence a Phase III …
-
Lindus Health and Quotient Sciences to support sponsors with trial recruitment
Lindus Health and Quotient Sciences have entered a strategic collaboration to support biotech and pharmaceutical sponsors with subject recruitment for …
-
ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida, from 6 to 9 December, updated …
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the US-based …
-
APAC’s rising stars beyond China
While China continues to dominate clinical trial activity across Asia-Pacific (APAC) and globally, other countries are rapidly emerging as significant …
-
UK MHRA clears Ensoma’s EN-374 trial application for X-CGD
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has cleared Ensoma’s clinical trial authorisation (CTA) application for its in …
-
EpilepsyGTx secures $33m to progress FRE therapy through Phase I/IIa trials
Biotechnology firm EpilepsyGTx has secured $33m in a Series A funding round to progress its adeno-associated viral (AAV) gene therapy, …
-
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC
Bristol Myers Squibb (BMS) and BioNTech's pumitamig has displayed promising efficacy and safety during a mid-stage trial in front and …
-
Roche posts second Phase III win for oral SERD
Roche’s oral selective oestrogen receptor degrader (SERD) has reduced the risk of invasive disease recurrence or death by 30% in …
-
ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL
At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, …
-
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label, …
-
Brazilian study links postnatal rapid weight gain to elevated paediatric BMI
Rapid weight gain in early life is a well-documented risk factor for childhood obesity, as well as the onset of …
